Physician profile
Sandy Tran
NPI 1801205638
$1,705.05
in general payments reported to CMS, 2019-2025
10 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $147 · 2022: $406 · 2023: $385 · 2024: $500 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,152.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $780.76 | 2021-2025 | Precision7, Precision 1, Total30 |
| Coopervision INC. | $177.87 | 2023-2024 | Misight Contact Lens, Paragon Crt |
| Johnson & Johnson Vision Care, INC. | $155.24 | 2021-2024 | Acuvue |
| Abbvie INC. | $123.66 | 2022 | |
| Apellis Pharmaceuticals, INC. | $121.81 | 2023 | Syfovre |
| Biotissue Holdings INC. | $120.58 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $120.06 | 2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $64.10 | 2022-2024 | Infuse |
| Oyster Point Pharma, INC. | $28.00 | 2024 | Ryzumvi, Tyrvaya |
| Sight Sciences, INC. | $12.97 | 2023 | Tearcare System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.